(NASDAQ: CRSP) Crispr Therapeutics Ag's forecast annual revenue growth rate of 170.25% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 59.84%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.7%.
Crispr Therapeutics Ag's revenue in 2025 is $37,314,000.On average, 11 Wall Street analysts forecast CRSP's revenue for 2025 to be $4,770,175,823, with the lowest CRSP revenue forecast at $205,858,738, and the highest CRSP revenue forecast at $15,302,166,162. On average, 9 Wall Street analysts forecast CRSP's revenue for 2026 to be $22,190,714,169, with the lowest CRSP revenue forecast at $223,013,632, and the highest CRSP revenue forecast at $124,776,127,328.
In 2027, CRSP is forecast to generate $74,170,216,961 in revenue, with the lowest revenue forecast at $11,102,647,915 and the highest revenue forecast at $192,237,751,129.